126 related articles for article (PubMed ID: 11026535)
21. Single-chain protein mimetics of the N-terminal heptad-repeat region of gp41 with potential as anti-HIV-1 drugs.
Crespillo S; Cámara-Artigas A; Casares S; Morel B; Cobos ES; Mateo PL; Mouz N; Martin CE; Roger MG; El Habib R; Su B; Moog C; Conejero-Lara F
Proc Natl Acad Sci U S A; 2014 Dec; 111(51):18207-12. PubMed ID: 25489108
[TBL] [Abstract][Full Text] [Related]
22. Core structure of gp41 from the HIV envelope glycoprotein.
Chan DC; Fass D; Berger JM; Kim PS
Cell; 1997 Apr; 89(2):263-73. PubMed ID: 9108481
[TBL] [Abstract][Full Text] [Related]
23. Potent D-peptide inhibitors of HIV-1 entry.
Welch BD; VanDemark AP; Heroux A; Hill CP; Kay MS
Proc Natl Acad Sci U S A; 2007 Oct; 104(43):16828-33. PubMed ID: 17942675
[TBL] [Abstract][Full Text] [Related]
24. Extremely Thermostabilizing Core Mutations in Coiled-Coil Mimetic Proteins of HIV-1 gp41 Produce Diverse Effects on Target Binding but Do Not Affect Their Inhibitory Activity.
Cano-Muñoz M; Cesaro S; Morel B; Lucas J; Moog C; Conejero-Lara F
Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33921495
[TBL] [Abstract][Full Text] [Related]
25. Thermodynamics of peptide inhibitor binding to HIV-1 gp41.
Cole JL; Garsky VM
Biochemistry; 2001 May; 40(19):5633-41. PubMed ID: 11341828
[TBL] [Abstract][Full Text] [Related]
26. Theaflavin derivatives in black tea and catechin derivatives in green tea inhibit HIV-1 entry by targeting gp41.
Liu S; Lu H; Zhao Q; He Y; Niu J; Debnath AK; Wu S; Jiang S
Biochim Biophys Acta; 2005 May; 1723(1-3):270-81. PubMed ID: 15823507
[TBL] [Abstract][Full Text] [Related]
27. Peptide and non-peptide HIV fusion inhibitors.
Jiang S; Zhao Q; Debnath AK
Curr Pharm Des; 2002; 8(8):563-80. PubMed ID: 11945159
[TBL] [Abstract][Full Text] [Related]
28. Structure-based design, synthesis and biological evaluation of new N-carboxyphenylpyrrole derivatives as HIV fusion inhibitors targeting gp41.
Wang Y; Lu H; Zhu Q; Jiang S; Liao Y
Bioorg Med Chem Lett; 2010 Jan; 20(1):189-92. PubMed ID: 19932616
[TBL] [Abstract][Full Text] [Related]
29. Hydrophobic mutations in buried polar residues enhance HIV-1 gp41 N-terminal heptad repeat-C-terminal heptad repeat interactions and C-peptides' anti-HIV activity.
Zheng B; Wang K; Lu L; Yu F; Cheng M; Jiang S; Liu K; Cai L
AIDS; 2014 Jun; 28(9):1251-60. PubMed ID: 24625369
[TBL] [Abstract][Full Text] [Related]
30. Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: conserved helical interactions underlie the broad inhibitory activity of gp41 peptides.
Malashkevich VN; Chan DC; Chutkowski CT; Kim PS
Proc Natl Acad Sci U S A; 1998 Aug; 95(16):9134-9. PubMed ID: 9689046
[TBL] [Abstract][Full Text] [Related]
31. Characterization and HIV-1 fusion inhibitory properties of monoclonal Fabs obtained from a human non-immune phage library selected against diverse epitopes of the ectodomain of HIV-1 gp41.
Louis JM; Bewley CA; Gustchina E; Aniana A; Clore GM
J Mol Biol; 2005 Nov; 353(5):945-51. PubMed ID: 16216270
[TBL] [Abstract][Full Text] [Related]
32. HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41.
Lawless MK; Barney S; Guthrie KI; Bucy TB; Petteway SR; Merutka G
Biochemistry; 1996 Oct; 35(42):13697-708. PubMed ID: 8885850
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of HIV type 1 infectivity by constrained alpha-helical peptides: implications for the viral fusion mechanism.
Judice JK; Tom JY; Huang W; Wrin T; Vennari J; Petropoulos CJ; McDowell RS
Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13426-30. PubMed ID: 9391041
[TBL] [Abstract][Full Text] [Related]
34. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV.
Gustchina E; Hummer G; Bewley CA; Clore GM
J Med Chem; 2005 Apr; 48(8):3036-44. PubMed ID: 15828842
[TBL] [Abstract][Full Text] [Related]
35. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.
Deng Y; Zheng Q; Ketas TJ; Moore JP; Lu M
Biochemistry; 2007 Apr; 46(14):4360-9. PubMed ID: 17371053
[TBL] [Abstract][Full Text] [Related]
36. A multi-functional peptide as an HIV-1 entry inhibitor based on self-concentration, recognition, and covalent attachment.
Zhao L; Tong P; Chen YX; Hu ZW; Wang K; Zhang YN; Zhao DS; Cai LF; Liu KL; Zhao YF; Li YM
Org Biomol Chem; 2012 Aug; 10(32):6512-20. PubMed ID: 22760295
[TBL] [Abstract][Full Text] [Related]
37. Conformation of trimeric envelope glycoproteins: the CD4-dependent membrane fusion mechanism of HIV-1.
Yingliang W; Hong Y; Zhijian C; Wenxin L
J Biomol Struct Dyn; 2007 Aug; 25(1):1-9. PubMed ID: 17676933
[TBL] [Abstract][Full Text] [Related]
38. Atomic structure of the ectodomain from HIV-1 gp41.
Weissenhorn W; Dessen A; Harrison SC; Skehel JJ; Wiley DC
Nature; 1997 May; 387(6631):426-30. PubMed ID: 9163431
[TBL] [Abstract][Full Text] [Related]
39. The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120.
Moseri A; Biron Z; Arshava B; Scherf T; Naider F; Anglister J
FEBS J; 2015 Dec; 282(24):4643-57. PubMed ID: 26432362
[TBL] [Abstract][Full Text] [Related]
40. High-throughput screening method of inhibitors that block the interaction between 2 helical regions of HIV-1 gp41.
Jin BS; Lee WK; Ahn K; Lee MK; Yu YG
J Biomol Screen; 2005 Feb; 10(1):13-9. PubMed ID: 15695339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
